In a recent study published in Cytokine & Growth Factor Reviews, researchers discussed the development of messenger ribonucleic acid (mRNA) vaccines against the respiratory syncytial virus (RSV).
MELBOURNE, Australia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral ...
The global respiratory disease vaccine market size was valued at USD 65.72 billion in 2025 and is predicted to hit around USD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback